About this event
Biosimilars have been in the market for 16 years since its first launch in 2006 in Europe, currently, there are 84 approvals in the EU and 35 in the US, representing almost 90% of the world market. While more biosimilars entering the healthcare system, there remains the need for broader information share and regular discussions to clarify and alleviate the concerns of biosimilars use for physicians and patients, specifically on the issues of prescribing practice and switching of biosimilars.
An academic clinician with specialty in gastroenterology, a pharmacist, a patient advocate and a market access expert will share their experience with biosimilars, highlighting successes and challenges, their perspectives on prescribing and switching of biosimilars and measures to increase biosimilar adoption, including the role of healthcare providers.
Enhanced knowledge on biosimilars use will help provide more affordable treatment choices for patients.
Eric David Hargan, JD, Former United States Deputy Secretary of Health and Human Services
Steven Stranne, MD, JD, Foley Hoag LLP
Eric David Hargan, JD
Michael S Reilly, Esq
Ralph McKibbin, MD, FACP, FACG, AGAF
Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP
Chad Pettit, MBA
Andrew Spiegel, Esq
To find out more about the webinar, click here to download the agenda
The mission of GaBI is to foster the worldwide efficient use of high quality and safe medicines at an affordable price, thus advancing and supporting the idea of accessible, affordable and sustainable health care.
Share this event